Scarica l'app Stockscreener
52.10
4.03%
-2.19
Precedente Chiudi:
$54.29
Aprire:
$53.9
Volume 24 ore:
3.00M
Relative Volume:
0.51
Capitalizzazione di mercato:
$9.40B
Reddito:
$1.36B
Utile/perdita netta:
$-302.91M
Rapporto P/E:
-30.32
EPS:
-1.7182
Flusso di cassa netto:
$-219.93M
1 W Prestazione:
+0.10%
1M Prestazione:
-11.20%
6M Prestazione:
+0.29%
1 anno Prestazione:
-27.22%
Intervallo 1D:
$51.76
$54.04
Intervallo di 1 settimana:
$51.63
$57.03
Portata 52W:
$40.77
$104.32
Tempus Ai Inc Stock (TEM) Company Profile
Nome
Tempus Ai Inc
Settore
Industria
Telefono
800-976-5448
Indirizzo
600 WEST CHICAGO AVENUE, CHICAGO
Compare TEM vs VEEV, BTSG, HQY, TXG
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TEM
Tempus Ai Inc
|
52.10 | 9.85B | 1.36B | -302.91M | -219.93M | -1.7182 |
VEEV
Veeva Systems Inc
|
243.75 | 39.23B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
61.71 | 11.81B | 13.65B | 169.86M | 412.12M | 1.0758 |
HQY
Healthequity Inc
|
104.73 | 8.82B | 1.34B | 230.70M | 440.96M | 2.6695 |
TXG
10 X Genomics Inc
|
56.09 | 7.52B | 638.78M | -22.66M | 122.18M | -0.1744 |
Tempus Ai Inc Stock (TEM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Iniziato | Jefferies | Underperform |
| 2026-04-13 | Aggiornamento | TD Cowen | Hold → Buy |
| 2026-02-19 | Iniziato | Mizuho | Outperform |
| 2026-02-17 | Iniziato | Robert W. Baird | Outperform |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-10-21 | Downgrade | TD Cowen | Buy → Hold |
| 2025-10-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-09-02 | Iniziato | H.C. Wainwright | Buy |
| 2025-04-21 | Iniziato | BTIG Research | Buy |
| 2025-02-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-02-12 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-02-05 | Ripresa | TD Cowen | Buy |
| 2024-12-13 | Iniziato | Wolfe Research | Outperform |
| 2024-12-09 | Iniziato | Guggenheim | Buy |
| 2024-11-11 | Downgrade | Stifel | Buy → Hold |
| 2024-10-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-08-12 | Iniziato | Piper Sandler | Neutral |
| 2024-07-09 | Iniziato | BofA Securities | Buy |
| 2024-07-09 | Iniziato | JP Morgan | Overweight |
| 2024-07-09 | Iniziato | Longbow | Buy |
| 2024-07-09 | Iniziato | Loop Capital | Buy |
| 2024-07-09 | Iniziato | Morgan Stanley | Overweight |
| 2024-07-09 | Iniziato | Needham | Buy |
| 2024-07-09 | Iniziato | Stifel | Buy |
| 2024-07-09 | Iniziato | TD Cowen | Buy |
| 2024-07-09 | Iniziato | William Blair | Outperform |
Mostra tutto
Tempus Ai Inc Borsa (TEM) Ultime notizie
Tempus AI, Inc. SEC Filing (Aug 14, 2026) - Stock Titan
Tempus AI (TEM) CEO, Data, discloses 62,239-share bona fide stock gift - Stock Titan
TEM to CAD: Tempus AI, Inc. • Robinhood Token Price in Canadian Dollar - CoinGecko
TEM to BDT: Tempus AI, Inc. • Robinhood Token Price in Bangladeshi Taka - CoinGecko
Dimensional Fund Advisors LP Has $1.85 Million Stock Holdings in Tempus AI, Inc. $TEM - MarketBeat
TEM to SGD: Tempus AI, Inc. • Robinhood Token Price in Singapore Dollar - CoinGecko
TEM to EUR: Tempus AI, Inc. • Robinhood Token Price in Euro - CoinGecko
Tempus AI, Inc. • Robinhood Token Price History: Download TEM Historical Data - CoinGecko
Tempus AI, Inc. • Robinhood Token (TEM) Price, MarketCap, Charts and Fundamentals Info - BeInCrypto
Tempus AI's FDA Win Could Unlock Major Reimbursement Growth Ahead - Zacks Investment Research
Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High? - The Globe and Mail
3 Stocks That May Be Trading Below Intrinsic Value Estimates By Up To 48.5% - simplywall.st
Tempus AI Expands Cancer Platform With Launch of ArteraAI Prostate Test For Metastatic Patients - stocktwits.com
Tempus AI CEO, data Ryan Fukushima sells $1,000,800 in shares By Investing.com - Investing.com Australia
Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells $1,000,800.00 in Stock - MarketBeat
Tempus AI Insider Sold Shares Worth $1,000,800, According to a Recent SEC Filing - Moomoo
Tempus AI CEO, data Ryan Fukushima sells $1,000,800 in shares - Investing.com
Tempus AI (TEM) executive’s spouse sells 20,000 shares under 10b5-1 plan - Stock Titan
Tempus Q2 Earnings Call Highlights Data Growth and Pricing Upside - The Globe and Mail
Bios Life leaves stealth with $25M and a Tempus alliance for cancer surveillance - The Next Web
Tempus AI (NASDAQ:TEM) Trading 7.5% HigherStill a Buy? - MarketBeat
Top Artificial Intelligence Stocks To Add to Your WatchlistAugust 10th - MarketBeat
Tempus AI, Inc. (TEM) Stock Analysis: 20.35% Potential Upside Amid Strong Revenue Growth - DirectorsTalk Interviews
Finivi Inc. Sells 24,340 Shares of Tempus AI, Inc. $TEM - MarketBeat
Tempus AI Inc (TEM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tempus AI Stock (TEM) Opinions on Analyst Ratings and Portfolio Holdings - Quiver Quantitative
TEM Surges Into $1.5B MRD Deal As Stock Pulls Back - StocksToTrade
Why Tempus AI (TEM) Is Up 18.6% After Joining CellCarta’s CDx Commercialization Lab Network - simplywall.st
Tempus AI Stock Drops As $1.5B Personalis Deal Ups The MRD Stakes - StocksToTrade
Tempus AI, Inc. • Robinhood Token (TEM) Price Prediction for 2026 to 2031 - Bybit
Terra Environmental (TEM): Vanessa Kubo plans $922K stock sale, details 10b5-1 trades - Stock Titan
Tempus AI, Inc. • Robinhood Token Price: TEM/USD Live Price Chart, Market Cap & News Today - CoinGecko
Why Is Tempus AI Stock Surging on Friday? - Benzinga
Spotlight On Tempus AI And 2 Other Leading Insider-Owned Growth Stocks - webull.com
Tempus Hub Will Support Oncology Test Orders in CellCarta Deal - Stock Titan
Tempus AI Insider Sold Shares Worth $1,100,076, According to a Recent SEC Filing - marketscreener.com
Tempus AI (NASDAQ:TEM) Director David Epstein Sells 370 Shares of Stock - MarketBeat
Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells 23,818 Shares - MarketBeat
Tempus AI, Inc. (TEM) director sells 370 shares under 10b5-1 plan - Stock Titan
Piper Sandler Keeps Their Hold Rating on Tempus AI, Inc. Class A (TEM) - theglobeandmail.com
Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications - Business Wire
H.C. Wainwright cuts Tempus AI stock price target to $56 on revenue miss - Investing.com
Tempus AI, Inc. Stock 12‑Month Price Target Cut to $62.21, Implies 42% Upside - TradingView
Tempus AI, Inc. (TEM) Stock Analysis: A Healthcare Tech Powerhouse with 48% Potential Upside - DirectorsTalk Interviews
BTIG cuts Tempus AI stock price target to $70 on model update - Investing.com
Tempus AI Inc : JP Morgan Cuts Target Price t - moomoo.com
Tempus AI Stock (TEM) Opinions on Recent Trading Activity and Corrections - Quiver Quantitative
InvestingPro spotted Tempus AI’s 43% decline 7 months in advance By Investing.com - Investing.com
Avidity Partners Management LP Purchases New Stake in Tempus AI, Inc. $TEM - MarketBeat
The Bull Case For Tempus AI (TEM) Could Change Following Profit Return, Outlook Hike And Personalis DealLearn Why - simplywall.st
Tempus AI (TEM) awards 40,000 RSUs to EVP and Chief Legal Officer - Stock Titan
Tempus Ai Inc Azioni (TEM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tempus Ai Inc Azioni (TEM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Fukushima Ryan | CEO, Data |
Aug 07 '26 |
Sale |
50.04 |
20,000 |
1,000,800 |
123,945 |
0.81%
1.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):